NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION.
Updated Rule 2.10 Announcement
Dublin, Ireland - August 1, 2014 - In accordance with Rule 2.10 of The City
Code on Takeovers and Mergers, Shire plc (LSE: SHP, NASDAQ: SHPG) confirms
that, as at close of business on July 31, 2014, it had in issue 589,538,765
ordinary shares of 5 pence each (excluding ordinary shares held in treasury),
with ISIN JE00B2QKY057, which carry voting rights of one vote per share.
Shire plc has an American Depositary Receipt program for which Citibank, N.A.
acts as Depositary. One American Depositary Share ("ADS") represents three
ordinary shares of 5 pence each, with ISIN US82481R1068. The ADSs trade on the
NASDAQ Global Select Market.
For further information please contact:
Investor Relations
Jeff Poulton jpoulton@shire.com +1 781 482 0945
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmology.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release
www.shire.com